Blepharitis

MONTEREY, Calif. — In this Healio Video Perspective from the Women in Ophthalmology Summer Symposium, Jennifer M. Loh, MD, discusses how cases of Demodex blepharitis can sometimes masquerade as severe dry eye disease.

In this Healio Video Perspective, Bobak Azamian, MD, PhD, CEO and co-founder of Tarsus Pharmaceuticals, discusses topline data from the Saturn-2 phase 3 study of TP-03 for the treatment of Demodex blepharitis.

Nine years ago, it started at the Hawaiian Eye meeting, where the Healio/Ocular Surgery News editors paved the way for me to write this Premium Channel column. This is now my 94th column, and I will hit my 100th submission mid-year.

NCX 4251 may be effective at reducing dry eye disease symptoms in a specific subgroup of patients, according to a press release from Nicox.

NCX 4251 did not meet the primary or secondary efficacy endpoints in a phase 2b clinical trial investigating the ophthalmic suspension in patients with acute exacerbations of blepharitis, according to a press release from Nicox.

Among children of all racial and ethnic groups, Hispanic/Latino, American Indian and Asian children developed chalazion at a higher rate, and those with meibomian gland disease or blepharitis were more likely to develop chalazia on multiple occasions.

The final patient has completed the treatment stage of a phase 2b clinical trial investigating NCX 4251 for blepharitis, according to a press release from Nicox.

ATLANTA — Treatment and procedure options that offer both cosmetic and functional ocular improvements have increased in recent years, providing better quality-of-life care, according to a presenter at this year’s SECO meeting.

As I approach my eighth year straight of writing this monthly column, I still enjoy my year in review submission the most.

Nicox has initiated a phase 2b clinical trial to evaluate NCX 4251 vs. placebo in patients with acute exacerbations of blepharitis, according to a press release.